The Phase 3 STELLAR-303 trial tested zanzalintinib plus atezolizumab against regorafenib in patients with previously treated, non-MSI-high metastatic colorectal cancer. The study produced mixed results but achieved its main goal in the overall patient population. The combination did not significantly improve overall survival in patients without active liver metastases, although survival was longer than with

A growing body of evidence shows that starting treatment before surgery, known as a neoadjuvant-first approach, is helping more patients with locally advanced or borderline resectable pancreatic cancer become eligible for surgery and achieve longer survival. Experts emphasize that the best outcomes come from combining chemotherapy, radiation, surgery, and multidisciplinary care rather than relying on

Six-year follow-up data from the GARNET trial show that the immunotherapy drug Dostarlimab-gxly continues to provide durable benefits for patients with advanced or recurrent dMMR/MSI-H endometrial cancer who previously had limited treatment options after platinum-based chemotherapy. At a median follow-up of nearly 69 months, the overall response rate remained 45.5%, while complete responses increased from

Results from the Phase 2 NIVEC trial suggest that neoadjuvant nivolumab (Opdivo) may offer a highly effective treatment option for patients with stage I to III resectable mismatch repair–deficient (dMMR) endometrial cancer. Among 22 patients treated with nivolumab before surgery, 68.2% achieved a clinical complete response, with no evidence of cancer detected on imaging or